News – Page 1088 – Endpoints News

Vaxart reverse merges its way onto Nasdaq, climbing aboard the Aviragen shell

8 years ago

In a strategic switch, Sumitomo Dainippon bags rights to a PhIII diabetes drug from Poxel in $300M deal

8 years ago

Atlas-incubated Kymera leaps out of stealth mode, joins the hunt for game-changing protein degradation drugs

8 years ago

Mereo bags rights to the latest AstraZeneca castoff, shifts focus; Neos rejects buyout offer

8 years ago

Novartis builds cancer pipeline with a new platform/drug buyout, bagging Advanced Accelerator Applications for $3.9B

8 years ago

Merck’s bad day: $310M for NotPetya, franchise drugs take a hit and now the EMA pushes back on Keytruda

8 years ago

Tocagen streamlines pivotal plans; Wave Life Sciences cuts ribbon on new manufacturing plant

8 years ago

With ‘breakthrough’ status and a handy nickname, BioMarin plots speedy PhIII for gene therapy

8 years ago

Brushing back biosims, a confident AbbVie outlines a blockbuster winning streak ahead for Humira

8 years ago

In a switch, Merck CEO signals he’s in a deal-making frame of mind

8 years ago

Biotech Peer Review: Magenta onboards five new VPs; BioInvent is hunting for a new CEO

8 years ago

First Celgene, now Gilead can’t accurately forecast drug sales revenue. How bad is this?

8 years ago

Tesaro wins FDA OK for an IV version of chemo drug, launches discovery deal with Evotec

8 years ago

PDL gets aggressive with an offer to buy out Neos Therapeutics

8 years ago

In a pre-Halloween fright show, Celgene just scared the hell out of Wall Street — shares crater

8 years ago

AbbVie boasts a PhIII sweep for top psoriasis contender risankizumab, but it has lots of competition

8 years ago

John Hood bags $90M for his quest to get fedratinib OK’d by FDA and catapult into the market

8 years ago

Amgen buries the last big CETP drug, marking the bitter end of a blockbuster quest

8 years ago

Yes, the FDA did just slap down PTC’s Duchenne MD drug for the third time

8 years ago

PDUFA date past, PTC still hasn’t said what the FDA’s verdict was; BioInvent searching for a new CEO

8 years ago

Sandoz raises questions with FDA draft guidance on statistical approaches for biosimilars

8 years ago

The Medicines Company brings out the ax, looking to jettison hundreds of jobs in top-to-bottom restructuring

8 years ago

Ablynx IPO raises $200M for its nanobody platform effort

8 years ago

Putting your subscription dollars to use: San Diego-based Brittany Meiling is joining Endpoints News

8 years ago

Publisher's note

First page Previous page 1085 1086 108710881089 1090 1091 Next page Last page